Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results

Hematology
I ThuretDora Bachir

Abstract

Deferoxamine (DFO) is an iron chelator used to treat iron overload in patients receiving chronic blood transfusions, and is usually administered as overnight subcutaneous infusions. ISOSFER was a prospective, observational, cross-sectional study conducted in metropolitan France that evaluated patient characteristics, quality of life (QoL), compliance and patient satisfaction with DFO monotherapy. Of 70 patients with either thalassemia, sickle cell disease or myelodysplastic syndromes, 30% were 'satisfied' or 'very satisfied' with DFO. Patients' SF-36 scores were lower than those of the general French population, and lower among patients with comorbidities and those dissatisfied with treatment. Although 72% of patients had good compliance to DFO, 57% reported missing at least one infusion in the previous month, and 82% of patients expressed a preference for oral therapy. These results suggest that QoL is severely compromised in patients receiving DFO, and that compliance is not optimal.

References

Dec 1, 1994·Baillière's Clinical Haematology·V Gabutti, C Borgna-Pignatti
Jan 1, 1996·Acta Haematologica·V Gabutti, A Piga
Nov 17, 1998·Journal of Clinical Epidemiology·A LeplègeT V Perneger
Dec 2, 2000·Transfusion Science·W BreuerZ I Cabantchik
Apr 25, 2001·European Journal of Clinical Pharmacology·R ArborettiUNKNOWN Italian Colaborative Group on Thalassarmia
Nov 13, 2001·British Journal of Haematology·J B Porter
Apr 30, 2002·Acta Haematologica·J Jaime CaroAndroulla Eleftheriou
Sep 30, 2006·Health and Quality of Life Outcomes·Linda AbetzDiana Rofail

❮ Previous
Next ❯

Citations

May 1, 2012·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·B FilhonJ-P Vannier
May 30, 2012·Clinical Journal of Oncology Nursing·Mary Laudon ThomasKaren Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.